Document Detail

The Use of Digoxin in Patients with Worsening Chronic Heart Failure Reconsidering an Old Drug to Reduce Hospital Admissions.
MedLine Citation:
PMID:  24613328     Owner:  NLM     Status:  Publisher    
Digoxin is the oldest cardiac drug still in contemporary use, yet its role in the management of patients with heart failure (HF) remains controversial. A purified cardiac glycoside derived from the foxglove plant, digoxin increases ejection fraction (EF), augments cardiac output, and reduces pulmonary capillary wedge pressure without causing deleterious increases in heart rate or decreases in blood pressure. Moreover, it is also a neurohormonal modulator at low doses. In the pivotal Digitalis Investigation Group (DIG) trial, digoxin therapy was shown to reduce all-cause and HF-specific hospitalizations but had no effect on survival. With the discovery of neurohormonal blockers capable of reducing mortality in HF with a reduced EF, the results of the DIG trial were viewed as neutral and its use declined precipitously. Although modern drug and device-based therapies have dramatically improved the survival of ambulatory HF patients, outcomes for patients with worsening chronic HF, defined as deteriorating signs and symptoms on standard therapy often leading to unscheduled clinic or emergency room visits or hospitalization, have largely remained unchanged over the last two decades. We critically review the evidence for digoxin, including its limitations, and provide a conceptual framework for future research.
Andrew P Ambrosy; Javed Butler; Ali Ahmed; Muthiah Vaduganathan; Dirk J van Veldhuisen; Wilson S Colucci; Mihai Gheorghiade
Related Documents :
23351228 - Physiology of hemodynamic homeostasis.
2499228 - Hypoxic hazards of traditional paper bag rebreathing in hyperventilating patients.
3369998 - Comparison of the tono-pen to the goldmann applanation tonometer.
24454978 - The risk of heart failure and cardiometabolic complications in obesity may be masked by...
1653768 - Effects of three sodium-potassium adenosine triphosphatase inhibitors.
23817818 - Accuracy of stop-cursor method for determining systolic and pulse pressure variation.
Publication Detail:
Type:  REVIEW     Date:  2014-2-21
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  -     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2014-3-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Preeclampsia and Future Cardiovascular Risk among Women: A Review.
Next Document:  Results of the Destination Therapy Post-FDA-Approval Study with a Continuous Flow Left Ventricular A...